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Abstract: Glioblastoma is an invasive tumor of the central nervous system. Tumor recurrence 
resulting from ineffective current treatments, mainly due to the blood–brain barrier, highlights the 
need for innovative therapeutic alternatives. The recent availability of nanotechnology represents a 
novel targeted strategy in cancer therapy. Natural products have received considerable attention for 
cancer therapy because of general lower side effects. Curcumin is a new candidate for anticancer 
treatment, but its low bioavailability and water solubility represent the main disadvantages of its 
use. Here, curcumin was efficiently encapsulated in a nontoxic nanocarrier, termed dendrosome, 
to overcome these problems. Dendrosomal curcumin was prepared as 142 nm spherical structures 
with constant physical and chemical stability. The inhibitory role of dendrosomal curcumin on 
the proliferation of U87MG cells, a cellular model of glioblastoma, was evaluated by considering 
master genes of pluripotency and regulatory miRNA (microribonucleic acid). Methylthiazol tetra-
zolium assay and flow cytometry were used to detect the antiproliferative effects of dendrosomal 
curcumin. Annexin-V-FLUOS and caspase assay were used to quantify apoptosis. Real-time poly-
merase chain reaction was used to analyze the expression of OCT4 (octamer binding protein 4) 
gene variants (OCT4A, OCT4B, and OCT4B1), SOX-2 (SRY [sex determining region Y]-box 2), 
Nanog, and miR-145. Dendrosomal curcumin efficiently suppresses U87MG cells growth with 
no cytotoxicity related to dendrosome. Additionally, the accumulation of cells in the SubG
1
 
phase was observed in a time- and dose-dependent manner as well as higher rates of apoptosis 
after dendrosomal curcumin treatment. Conversely, nonneoplastic cells were not affected by this 
formulation. Dendrosomal curcumin significantly decreased the relative expression of OCT4A, 
OCT4B1, SOX-2, and Nanog along with noticeable overexpression of miR-145 as the upstream 
regulator. This suggests that dendrosomal curcumin reduces the proliferation of U87MG cells 
through the downregulation of OCT4 (octamer binding protein 4) variants and SOX-2 (SRY [sex 
determining region Y]-box 2) in an miR-145-dependent manner.
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Introduction
Glioblastoma is characterized by a high potential for growth and invasion. Insensitivity 
of this tumor to general therapies, including radio- and chemotherapy, leads to a high 
rate of recurrence. Until now, little was known about the genetic mechanisms involved 
in gliomagenesis.1–4 A positive association between the overexpression of stem cell 
marker genes and progression/metastasis of tumors triggered the idea that targeting 
of self-renewal pathways can be applied as a powerful approach in cancer treatment.5 
Transcription factors, OCT4 (octamer binding protein 4), SOX-2 (SRY [sex determin-
ing region Y]-box 2), and Nanog play crucial roles in the maintenance of stemness in 
both embryonic and somatic stem cells.6 Several studies have reported the oncogenic 
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role of these transcription factors in glioblastoma cells.2,3,7,8 
Regulation of these pluripotency factors is under the control 
of a subset of micro ribonucleic acids (miRNAs), which are 
favorably expressed in undifferentiated stem cells. The pro-
moter regions of these miRNAs and pluripotency factors are 
implicated in a precise reciprocal interaction giving rise to 
cell pluripotency or differentiation.6 miR-145 is well under-
stood in stemness pathways. It has been demonstrated that 
miR-145 induces differentiation in stem cells by suppressing 
the promoter of OCT4 and SOX-2.9,10 This explains the cause 
of low level miR-145 expression in most cancers.11 There is 
a considerable attention to replacing the chemical anticancer 
treatment agents with plant-based formulations to mitigate 
the undesirable effects during the prolonged treatment of 
patients. Curcumin is a hydrophobic compound extracted 
from the rhizome of Curcuma longa, which is employed as a 
spice and coloring agent in most Asian countries. A growing 
body of evidence has substantiated the antitumor properties 
of curcumin in various cancer cells through interaction with 
multiple signaling pathways.12–15 However, low water solubility, 
poor uptake and tissue distribution remain major obstacles, 
limiting the use of curcumin as an anticancer treatment agent.16 
Recently, scientists have revealed several strategies, such as 
loading synthetic analogs from turmeric, designing metabolic 
inhibitors and liposomal formulations, and nanoparticles of 
curcumin, to overcome these problems.17–20 Dendrosome was 
introduced as a novel neutral, amphipathic, and biodegrad-
able nanocarrier for a gene delivery system in the authors’ 
research group.21,22 The high potential of dendrosome as a 
gene porter led to the hypothesis that it can be exploited as 
a vehicle for curcumin delivery. The anticancer properties of 
dendrosomal curcumin (DNC) have been explored in mice 
models of fibrosarcoma and colon cancer.21–24 It was demon-
strated that dendrosome improves the solubility of curcumin 
and facilitates its uptake by cancer cells, suggesting that this 
polymer could open new avenues for successful drug delivery 
in cancer therapy.23,24 The present study reports for the first time 
a full characterization of DNC and describes the underlying 
mechanism through which curcumin targets the pluripotency 
pathways of glioblastoma cancer cells. U87MG – a cellular 
model of grade IV glioblastoma – was used in this regard. The 
probable cytotoxicity of this formulation on normal stem cells 
and fibroblast cells was also evaluated to determine if DNC 
can be considered a safe preparation for use in clinical and 
pharmaceutical approaches.
Material and methods
chemicals and standards
Curcumin was purchased from Merck KGaA (Darmstadt, 
Germany) with purity of 95%. Materials for the preparation of 
dendrosome were oleoyl chloride and polyethylene glycol 400 
that was purchased from Sigma-Aldrich (St Louis, MO, USA), 
and chloroform and triethyl amine were purchased from Merck. 
All the solvents used were high-performance liquid chroma-
tography (HPLC) grade from Merck; 85% formic acid was 
provided by Carlo Erba Reagents (Cornaredo, Italy). Water was 
purified by a Milli-Q® Plus system from EMD Millipore (Bil-
lerica, MA, USA). Phosphate-buffered saline (PBS) solution 
was from Sigma-Aldrich. Curcumin reference standard (10 mg) 
was provided by Extrasynthese (Genay Cedex, France).
Polymeric micelle Oa400 carrier 
(dendrosome) preparation
synthesis of dendrosome
The OA400 carrier was synthesized by esterification of oleoyl 
chloride (0.01 mol) and polyethylene glycol 400 (0.01 mol) in 
the presence of triethyl amine (0.012 mol) and chloroform as 
the solvent at 25°C for 4 hours. Triethylamine hydrochloride 
salt was filtered from its organic phase. Then, chloroform was 
evaporated from OA400 in vacuum oven at 40°C for 4 hours 
(Figure 1). Fourier transform infrared spectroscopy (Spec-
trum One, PerkinElmer, Inc., Shelton, CT, USA) analysis was 
H3C
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Figure 1 synthesis of the Oa400 carrier.
Abbreviation: Peg, polyethylene glycol.
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performed to confirm the dendrosomal chemical structure. 
The Fourier transform infrared spectrum of OA400 shows a 
stretching band of C-H aliphatic at 2,921 cm-1, a stretch-
ing band of C-H unsaturated aliphatic at 3,002 cm-1, and a 
stretching band carbonyl group of ester bands at 1,732 cm-1. 
The C-H bending vibration of CH
2
 and the C-H bending 
vibration of CH
3
 can be seen at 1,462 cm-1 and 1,350 cm-1, 
respectively. The C-O stretching vibration was at 1,111 cm-1 
as a broad band. The C=C stretching vibration can be seen 
at 1,651 cm-1 (Figure S1).
Preparation of the DNc
DNC preparation was performed using optimized protocol 
in the authors’ lab.23 Briefly, different weight/weight ratios 
of dendrosome/curcumin ranging from 50:1 to 10:1 were 
examined before settling on a suitable ratio of 25:1. Curcumin 
was dissolved in various amounts of dendrosome and checked 
for absorbance spectra by ultraviolet spectrophotometry 
(Infinite® 200 PRO, Tecan, Mannedorf, Switzerland). Then, 
the appropriate mixture of dendrosome and curcumin was 
evaluated for excitation/emission value in comparison with 
curcumin dissolved in PBS and 1% methanol as the control 
samples.23 The loading of dendrosome nanocarriers with 
curcumin molecules was performed using Gou et al’s proto-
col.25 Briefly, curcumin and dendrosome were co-dissolved 
in 5 mL acetone; this solution was added into 5 mL PBS 
while stirring constantly. Then, the acetone was evaporated 
in a rotary evaporator. The curcumin/dendrosome micelle 
solution was sterilized using a 0.22 µm syringe filter (EMD 
Millipore).25 Finally, the prepared DNC were stored at 4°C 
in a light-protected condition until used.23 For in vitro experi-
ments, DNC was diluted in complete culture medium.
In vitro characterization
Particle characterization of the dendrosomal 
formulation
DNC particle size was measured by dynamic light scatter-
ing (DLS) (Zetasizer® Nano ZS90; Malvern Instruments, 
Malvern, UK). Time correlation functions were analyzed 
to obtain the hydrodynamic diameter of the particles and 
the particle size distribution (polydispersity index [PDI]) 
using ALV-60X0 software V.3.X (Malvern). Autocorrelation 
functions were analyzed by the cumulant method fitting a 
single exponential to the correlation function to obtain the 
mean size, PDI, and distribution method (to fit a multiple 
exponential to the correlation function to obtain particle 
size distributions). Scattering was measured in an optical 
quality 4 mL borosilicate cell at a 90-degree angle. For 
these measurements, 20 µL DNC dispersion was diluted 
100-fold with PBS.  Measurements were carried out at the 
set temperature of 25°C.
electrophoretic mobility
The superficial charge (ζ-potentials) of the DNC systems was 
measured using a Zetasizer Nano ZS90 (Malvern). For all 
samples, an average of three measurements at the stationary 
level was taken. The temperature was kept constant at 25°C 
by a temperature controller. The ζ-potential was calculated 
from the electrophoretic mobility (µ
E
) using the Henry cor-
rection to Smoluchowski’s equation.
Encapsulation efficacy
Free curcumin were removed by means of dialysis. DNC was 
transferred in a dialysis bag. This dialysis bag was stirred in 
360 mL PBS at room temperature for 2 hours. The aqueous 
medium was refreshed once. The content of curcumin into the 
dendrosome was quantified by HPLC with diode array detec-
tion (HPLC-DAD) analysis, using curcumin as an external 
standard. The curcumin encapsulation yield is expressed as 
the so-called encapsulation efficiency (EE), which is defined 
as the percentage amount of curcumin entrapped in the den-
drosome in relation to the total amount of curcumin present 
during the DNC formation and entrapment procedure.
The curcumin-loaded concentration was assayed by HPLC-
DAD analysis performed using the HP 1100 equipped with 
an HP 1040 DAD, an automatic injector, an auto sampler, and 
a column oven, and managed by the HP 9000 workstation 
(Agilent Technologies, Santa Clara, CA, USA). The ultraviolet-
visible spectra were recorded between 220–500 nm and the 
chromatographic profiles were registered at 240, 330, 420, 
and 430 nm. Separations were performed on a reversed-phase 
column Luna® RP C18 (150 mm×3 mm id, 5 µm; Phenomenex, 
Torrance, CA, USA) maintained at 26°C. The eluents were H
2
O 
at pH 3.2 by formic acid (A) and acetonitrile (B). The following 
multistep linear gradient was applied: from 82% A to 56% A 
in 10 minutes, with a plateau of 3 minutes, in 14 minutes to 
48% B, and then 5 minutes to 80% of B. Total time of analysis 
was 32 minutes, equilibration time was 5 minutes, flow rate 
was 0.4 mL⋅min-1, and injection volume was 5 µL.
Transmission electron microscopy analysis
A drop (10 µL) of DNC dispersion diluted ten times was 
applied to a carbon film-covered copper grid (Società Italiana 
Chimici, Rome, Italy). Most of the dispersion was blotted 
from the grid with filter paper to form a thin film specimen, 
which was stained with a phosphotungstic acid solution 1% 
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weight/volume in sterile water. The samples were dried for 
3 minutes and then examined under a JEOL 1010 electron 
microscope (JEOL, Tokyo, Japan) and photographed at an 
accelerating voltage of 64 kV.
stability studies
The stability of DNC was studied according to the authors’ 
previous work.26,27 DNC was kept at 4°C±1°C, and at fixed 
time intervals they were assayed for their physical and chemi-
cal stability. Physical stability was checked by monitoring the 
size and PDI using DLS measurements. Chemical stability 
was checked by quantification of drug content after disruption 
of purified vesicles using HPLC-DAD analysis.
In vitro assessment of the anticancer 
effect of DNc
cell lines and culture condition
Glioblastoma cancer cell lines (U87MG), human bone 
marrow-derived stem cells (hBMSC), and normal human 
fibroblastic cells (HFSF-PI3) were obtained from the national 
cell bank of the Pasteur Institute, Tehran, Iran. U87MG, 
hBMSC, and HFSF-PI3 cells were cultured in Gibco® RPMI 
1640 medium and Gibco® low and high glucose Dulbecco’s 
Modified Eagle Medium (Life Technologies, Carlsbad, CA, 
USA), respectively. Cells were supplemented with 10% fetal 
bovine serum, 100 U/mL penicillin, and 100 mg/mL strepto-
mycin (Life Technologies). All cells were grown at 37°C in a 
humidified atmosphere of 5% carbon dioxide.
cell viability assay
Cell viability was assessed by methylthiazol tetrazolium 
(MTT) assay (Sigma-Aldrich) according to the manufac-
turer’s instruction. Briefly, cells were plated onto 96-well 
plates, respectively. After 24 hours, the cells were incubated 
for 24, 48, and 72 hours in the absence or presence of dif-
ferent concentrations of DNC. Dendrosome alone was used 
to test the cytotoxicity of the nanocarriers. After the treat-
ment, media containing the treatment agents were carefully 
removed and cells were washed twice with PBS before 20 µL 
medium containing 5 mg/mL MTT in PBS was added to each 
well. After 4 hours at 37°C, the medium was totally removed 
and 200 µL dimethyl sulfoxide solution was added to each 
well. The absorbance being proportional to cell viability 
was subsequently measured at 570 nm in each well using an 
enzyme-linked immunosorbent assay plate reader. All values 
were compared to the corresponding controls. Cell viability 
was calculated as the percentage of cell viability of treated 
cells against control cells.
cell cycle analysis
The effect of DNC on cell cycle distribution was assessed 
by flow cytometry after staining the cells with propidium 
iodide (PI). Briefly, 0.3×106 cells (U87MG) were seeded 
onto six-well plates and allowed to attach overnight. The 
previous medium was replaced with a fresh one contain-
ing the desired concentrations of DNC. After incubating 
for specified times, cells were collected and washed twice 
with cold PBS and fixed with ice-cold 70% ethanol at 4°C 
overnight. After washing twice with cold PBS, cells were 
resuspended in PBS containing 50 µg/mL PI, 0.1% sodium 
citrate, and 0.1 Triton X-100 followed by shaking at 37°C 
for 15 minutes. More than 104 cells were analyzed using a 
FACSCalibur™ flow cytometer (BD Biosciences, San Jose, 
CA, USA) and the data were consequently evaluated using 
Cell Quest software (BD Biosciences). Cells with a lower 
DNA content than those of the G
0
/G
1
 phase were referred to 
as apoptotic cells. The percentage of cells in each phase of 
the cell cycle was determined by at least three independent 
tests and the results were expressed as mean ± standard 
deviation.
apoptosis detection
Annexin-V-FLUOS and PI staining kit (Roche Applied 
Science, Penzberg, Germany) was used for apoptosis 
detection following the manufacturer’s instruction. Briefly, 
U87MG cells were seeded (0.3×106 cells/well) onto six-
well plates and allowed to adhere overnight to be treated 
with desired concentrations of DNC for 12, 24, and 
36 hours. Trypsin-digested cells were centrifuged at 200 g 
for 5 minutes. The cell pellet was resuspended in 100 µL 
Annexin-V-FLUOS labeling solution and incubated for 
10–15 minutes at 15°C–20°C and immediately analyzed 
by FACSCalibur flow cytometer.
caspase activity
Caspase activity was measured by the homogeneous caspase 
assay kit (Roche) according to manufacturer’s instructions. 
Enzymatic activity of caspase-2, 3, 6, 7, 8, 9, and 10 were 
determined using this assay. Cells were cultured onto 
96-well plates (2×104 cell/well) and treated with various 
concentrations of DNC at different intervals. The amount of 
free rhodamine 110 resulting from cleavage of the caspase 
substrate (DEVD-rhodamine 110) was fluorometrically 
determined at an excitation and emission wavelength of 
499 nm and 521 nm, respectively. Data were expressed 
as relative fluorescence units by Gene 5 software with a 
fluorescence plate reader (Synergy™ H4 Hybrid Reader; 
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BioTek, Winooski, VT, USA). Three independent tests 
were performed and the ratio between the treatment and 
control group was calculated. Data were expressed as 
mean ±  standard deviation.
rNa extraction and real-time polymerase  
chain reaction (Pcr)
Total RNA was extracted using TRIzol® reagent (Life 
Technologies) followed by DNase I digestion (Thermo Fisher 
Scientific, Waltham, MA, USA). Complementary DNA was 
synthesized by PrimeScript™ RT reagent kit (Takara Bio 
Inc, Shiga, Japan). The list of primers for specific genes and 
housekeeping gene glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH) are indicated in Table 1. Real-time PCR was 
performed using the SYBR® Premix Ex Taq™ II (Takara). 
Relative gene expression was calculated as 2-∆∆Ct.
mirNa expression analysis
The expression of miR-145 and U6 (reference gene) was 
analyzed using universal specific primer sets and  miRCURY 
LNA™ Universal RT microRNA PCR (Exiqon A/S, 
 Vedbaek, Denmark).
statistical analysis
Statistics were presented in Prism® 5 software (GraphPad 
Software, Inc, La Jolla, CA, USA) and analyzed using one-
way analysis of variance followed by Newman–Keuls multiple 
comparison test or Student’s t-test. Differences among groups 
were stated to be statistically significant when P,0.05.
Results
In vitro characterization  
of DNc formulation
Dimensional analysis, superficial charge,  
and loading efficiency of DNC
DNC was analyzed in terms of size, PDI, and ζ-potential 
measured by DLS analysis and in terms of encapsula-
tion efficacy by HPLC-DAD analysis. Regarding DLS 
measurements, correlation coefficients were superior to 
0.9, which means that the signal related to noise ratio 
was good (10%) (Figure 2A). The mean diameter of DNC 
was #200 nm by distribution algorithm-calculated DLS 
analysis (Figure 2B and D), and was suitable for systemic 
administration. PDI is a dimensionless measurement of 
the broadness size distribution calculated from distribution 
algorithm, and values were calculated for each peak as 
peak width/mean diameter. As summarized in Figure 2D, 
PDI was 0.4; therefore, the colloidal suspension of DNC 
was polydispersed. The measurements performed three 
times were nicely reproducible. The ζ-potential was 
around -7 mV, an acceptable value that does not indicate 
long-term stability. The curcumin loading efficiency was 
very high (87%). Transmission electron micrographs by 
positive stain provided important details on the morphology 
and dimension of the vesicles. DNC were sphere shaped 
and had a size comparable with the results from DLS 
analysis (Figure 2C) considering the different physical 
principles the two techniques were based on.
Physical and chemical stability tests of DNc
The physical stability of DNC was checked by monitoring 
size and PDI over time using DLS measurements. Size was 
maintained within 10 days (Figure 3A), and although PDI 
increased to 0.6 at day 16, it was constant within 10 days 
after DNC preparation (0.4). According to these results, 
no vesicle size alterations or homogeneity loss of the 
sample occurred within 10 days (Figure 3A). Additionally, 
chemical stability was checked by quantification of drug 
content after disruption of purified vesicles. As described 
in the experimental section, the content of curcumin into 
the dendrosome was quantified by HPLC-DAD analysis. 
The chemical stability of curcumin into the dendrosome 
was maintained at a constant level (not less than 93.8% 
residual percentage) at least 16 days after their prepara-
tion (Figure 3B). Both physical and chemical stabilities 
(in terms of residual percentage of drug) were acceptable 
for 10 days.
Table 1 List of the sets of primers for specific genes or for the 
housekeeping gene, GAPDH, used in real-time polymerase chain 
reaction assay
Gene Designed oligonucleotide Amplicon 
length 
(bp)
OCT4A F: TcgcaagcccTcaTTTc 
r: ccaTcaccTccaccaccT
113
OCT4B F: agaTTgaTaacTggTgTgTTTaTgTTc 
r: gcTgaaTaccTTcccaaaTagaac
191
OCT4B1 F: ggTTcTaTTTggTgggTTcc 
r: TTcTcccTcTcccTacTccTc
130
SOX-2 F: aagacTaggacTgagagaaagaagag 
r: aagagagaggcaaacTggaaTc
171
Nanog F: aaTaccTcagccTccagcagaTg 
r: TgcgTcacaccaTTgcTaTTcTTc
148
GAPDH F: gTgaaccaTgagaagTaTgacaac 
r: caTgagTccTTccacgaTacc
 
123
Abbreviations: F, forward primer; r, reverse primer; GAPDH, glyceraldehyde 
3-phosphate dehydrogenase; OCT4, octamer binding protein 4; SOX-2, SRY (sex determining 
region Y)-box 2.
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In vitro assessment of anticancer  
effect of DNc
DNc induces cell death in U87Mg  
in a time- and dose-dependent manner
The sensitivity of U87MG cells as well as hBMSC and HFSF-
PI3 cells to DNC, free curcumin, and empty dendrosome 
were studied using MTT assay. As shown in Figure 4, DNC 
significantly suppressed the proliferation of U87MG cells 
in a time- and dose dependent manner. The half maximal 
inhibitory concentration (IC
50
) of DNC for U87MG cells was 
20 µM after 24 hours (Figure 4A) and 48 hours (Figure 4B), 
which declined to 10 µM at 72 hours (Figure 4C) (P,0.001). 
However, the viability of U87MG was not affected by free 
curcumin only at 72 hours (Figure 4C). On the other hand, 
no inhibitory effect was observed for dendrosome alone. In 
total, these findings demonstrate that dendrosome increased 
the water solubility and entry of curcumin to cells without any 
toxic effects correlated with dendrosomes as a carrier. Studying 
the inhibitory effects of DNC on hBMSC showed that these 
cells are affected by DNC as well as cancerous cells and in a 
concentration higher than in U87MG cells. Figure 5A shows 
the effects of DNC on cell viability of hBMSC after 24 hours 
of drug exposure. Cell viability declined to 67% after treatment 
with 25 µM DNC (P,0.01) and to 35% and 31% after treat-
ment with 30 µM and 35 µM DNC, respectively (P,0.001). 
The loss of cell viability was also determined after 48 hours of 
treatment with DNC (Figure 5B). The cell viability declined to 
54% and 52% after treatment with 30 µM and 35 µM DNC, 
respectively (P,0.05). The viability of HFSF-PI3 was not sig-
nificantly affected due to treatment and at determined IC
50
 for 
U87MG lines, no inhibitory effect was detected on these cells 
(P.0.05); however, at 25 µM concentration, the viability of 
the cells decreased to 50% (Figure 6) (P,0.01). Therefore, in 
concentrations suppressive for cancer cells, no harmful effects 
connected to DNC were observed in stem cells and normal 
fibroblast cells, showing the safety of this formulation as an 
anticancer treatment agent on normal cells.
The effects of DNc on the U87Mg  
cell cycle distribution
To achieve further insight into the mechanism of the growth 
inhibitory effects of DNC, U87MG cells were treated in con-
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centrations close to the IC
50
 (15, 17.5, and 20 µM) obtained in 
the MTT assay. Treated cells analyzed for cell cycle distribution 
were compared to the control. By increasing the concentration 
of DNC at 24 hours of treatment, the cell population in the 
SubG
1
 phase significantly increased (P=0.0006). Cells in the G
1
 
or S phase gradually decreased, but not at a statistically signifi-
cant rate (G
1
: P=0.06; S: P=0.3). Surprisingly, cells in the G
2
/M 
phase were significantly reduced (P=0.0147), consistent with 
the fact that DNC can target the cell division and proliferation 
pathways (Figure 7A–C and Table 2). By increasing the time 
of treatment to 36 hours, an increased cell death rate in the 
SubG
1
 phase (P=0.0036) together with a gradual decrease in 
the G
1
 phase (P=0.0029) showed that enhancing the incubation 
time resulted in probable inhibition of the cell growth pathway 
(Figure 8). Increasing incubation time from 12 hours to 24 hours 
led to a significant increase in the SubG
1
 cell population 
(P=0.0215). However, the rate of cell death slightly decreased 
at 36 hours compared with 24 hours (Figure 7D, E and Table 3). 
The cell population in the G
2
/M and S phases decreased, 
although these changes were not significant (data not shown). 
Altogether, these data show that DNC induced cell death in a 
time- and dose-dependent manner in U87MG cells.
DNc triggers apoptosis in U87Mg cells
To determine the mode of cell death (apoptosis or necrosis) 
induced by DNC, Annexin-V-FLUOS and PI staining were 
applied to separate intact cells, early apoptosis, late apoptosis, 
and necrotic cells. Different concentrations of DNC (15, 17.5, 
and 20 µM) were subjected to U87MG after 12, 24, and 
36 hours of treatment. As indicated in Figure 9A, DNC 
induced apoptosis in a time- and dose-dependent manner. 
Percentages of early apoptosis after 12, 24, and 36 hours of 
treatment with 17.5 µM were determined as 26.09%±0.007%, 
30.2%±0.02%, and 34.75%±0%, respectively (P=0.02).
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elevated rate of caspase activity in U87Mg  
after DNc treatment
The potential of DNC to activate caspase during apoptosis 
was determined in a time- and dose-dependent manner. 
Different concentrations of DNC (15, 17.5, and 20 µM) 
were subjected to U87MG after 12, 24, and 36 hours of 
treatment. As illustrated in Figure 9B, DNC induced caspase 
activation in a time-dependent behavior. Treatment with 
17.5 µM DNC resulted in 1.32±0.08-fold, 2.34±0.1-fold, 
and 3.49±0.009-fold elevated caspase activity in U87MG 
cells after 12, 24, and 36 hours of exposure, respectively 
(P,0.0001).
DNc inhibits U87Mg cells by silencing  
the expression of pluripotency transcription  
factors including OCT4A, OCT4B1, SOX-2, and Nanog
Real-time PCR was used to study the effect of DNC on 
the expression of pluripotency genes including OCT4A 
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variants (A, B, and B1), SOX-2, and Nanog after treatment 
with 17.5 µM DNC at 12, 24, and 36 hours post-treatment. 
Designed OCT4 primer sets are potent to discriminate 
between all OCT4 variants and related pseudogenes. In 
normal culture conditions, the OCT4A variant is weakly 
expressed in U87MG and negative expression was 
observed for the OCT4B variant but OCT4B1, SOX-2, and 
Nanog were noticeably expressed in U87MG, suggesting 
that these genes are more important for proliferation in 
U87MG cells. As shown in Figure 10A, expression of the 
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OCT4A variant (P,0.0001), OCT4B1 variant (P=0.0048), 
SOX-2 (P,0.0001), and Nanog (P=0.007) significantly 
decreased after 36 hours of treatment with 17.5 µM DNC.
DNc activated miR-145 expression in U87Mg cells
The effect of DNC on the expression of miR-145 was 
investigated. miR-145 is related to the suppression of genes 
implicated in pluripotency (OCT4 and SOX-2). An increased 
level of miR-145 can be observed during differentiation. An 
effect of DNC on miR-145 expression was examined after 
24 hours of treatment with 17.5 µM DNC. As shown in Fig-
ure 10B, miR-145 expression was elevated approximately 
34.35±3.9-fold in comparison with nontreated control 
cells (P=0.005). The results show that DNC decreased the 
expression of OCT4A, OCT4B1, and SOX-2 in an miR-145-
dependent manner.
Discussion
Glioblastoma is one of the most invasive and heterogenic 
primary tumors in the central nervous system, with an 
average survival rate of 1 year. Tumor resection combined 
with radio- and chemotherapy is the current strategy to treat 
patients with glioblastoma. The lack of clear margin in glioma 
tumors results in incomplete resection and tumor recurrence. 
Additionally, the blood–brain barrier prevents the diffusion 
of large hydrophobic and ionic molecules to the tumor, mak-
ing the use of systemically delivered drugs poorly effective. 
The injection of therapeutic agents into a surgically resected 
tumor or transient disruption of the blood–brain barrier is 
a technique suggested to bypass such shortcomings.28,29 In 
spite of the clinical and technical progress in glioblastoma 
therapy, the mortality rate of this tumor remains high.30 At 
present, the increasing knowledge of nanotechnology prom-
ises to be helpful in the development of localized delivery 
of therapeutic agents by means of nanocarriers with small 
particle size.31 Here, curcumin was efficiently encapsulated 
in dendrosome micellar structures. The pleiotropic features 
of curcumin to affect multiple signaling pathways and its 
preferential targeting of cancer cells rather than normal 
cells makes it an attractive agent for cancer therapy,32,33 and 
it is safe even at high doses.34 Given the well-known limita-
tions of glioblastoma treatment strategies, the role of DNC 
on the proliferation of U87MG – a cellular model of grade IV 
glioblastoma – was evaluated. The oncogenic characteristics 
of pluripotency factors including OCT4, SOX-2, and Nanog 
in glioma cells has been previously reported, feeding into 
formation of the idea that targeting pluripotency genes may 
represent a novel approach to providing better treatment for 
this type of cancer.2,5,7,8 Here, the expression of two OCT4 
variants (A and B), SOX-2, and Nanog, as markers of stem-
ness after treatment with DNC, was measured. Moreover, 
Table 2 cell cycle distribution in U87Mg cells after 24-hour 
dose-dependent treatment of the cells with dendrosomal 
curcumin using flow cytometry analysis
DNC (μM) Cell phase
SubG1 (%) G1 (%) S (%) G2/M (%)
0 3.99±0.004 39.35±0.005 10±0.04 27.45±0.01
15 27.05±0.004 32.18±0.06 8.49±0.008 20.28±0.03
17.5 56±0.02 27±0.006 6±0.03 10±0.04
20 57.62±0.07 26.61±0.02 3.95±0.001 8.92±0.1
Note: Data expressed as mean ± standard deviation.
Abbreviation: DNc, dendrosomal curcumin.
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OCT4B1, a novel variant of OCT4 formerly demonstrated 
by the authors’ research group as a gene involved in the 
pluripotency pathway,35 was evaluated. However, the onco-
genic roles of OCT4 as a result of related pseudogenes are 
still controversial.36–38 Most of this controversy regarding 
OCT4 expression is related to OCT4A, which has a strong 
similarity to OCT4 pseudogenes. The OCT4 primer sets used 
in the present study are effective in discriminating between 
all OCT4 variants and related pseudogenes.35
In vitro characterization of DNC conf irmed that 
dendrosomes have efficiently encapsulated curcumin in 
142 nm spherical structures, which makes it suitable for 
systemic administration. Analysis of the physical and 
chemical stability confirmed that DNC has a constant 
diameter and drug content even 16 days after preparation 
of this formulation. Data from both MTT assay and flow 
cytometry show that DNC induced cell death in U87MG 
cells in a time- and dose-dependent manner, significantly 
increasing the SubG
1
 fraction and reducing the cell popu-
lation in G
2
/M. Together, these data indicate that DNC 
targets the proliferation pathways in U87MG cells. After 
36 hours of exposure the G
1
 phase fraction was reduced 
and the SubG
1
 peak was increased, indicating that U87MG 
growth was inhibited with longer exposure time. Of note, 
there was no cytotoxicity related to the empty dendrosome 
in U87MG cells. The effects of DNC in both hBMSC and 
HFSF-PI3 cells were also examined to explore the possible 
cytotoxic effects on nonneoplastic cells. Calculation of the 
IC
50
 values in these cells clearly indicates that cell death 
occurs in a concentration higher than the one effective 
in cancer cells. These results may also indicate DNC has 
preferential uptake in cancer cells relative to normal cells, 
Table 3 cell cycle distribution in U87Mg cells after time-
dependent treatment of the cells with 17.5 µM dendrosomal 
curcumin using flow cytometry analysis
Cell phase t=0 t=12 hours t=24 hours t=36 hours
subg1 (%) 3.9±0.004 37±0.03 56±0.02 47±0.007
g1 (%) 39.35±0.005 44±0.1 27±0.006 22±0.004
s (%) 10.09±0.03 6±0.02 6±0.03 7±0.02
g2/M (%) 27.45±0.01 11.75 10±0.03 19±0.01
Note: Data expressed as mean ± standard deviation.
Abbreviation: t, time.
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Figure 9 (A) Dendrosomal curcumin-induced apoptosis using annexin-V-FlUOs/propidium iodide (PI) staining in U87Mg cells. Viable cells (annexin-V-/PI-), early 
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as previously mentioned. Protein composition as well as 
membrane structure diversity between tumor and normal 
cells could be responsible for drug sensitivity.23,32,39 Addi-
tionally, DNC can be considered a safe formulation for 
cancer therapy and clinical applications. Apoptosis depends 
on caspase activation,40 and the role of curcumin in induc-
ing this biologic effect has been investigated in numerous 
studies that demonstrated its potential to activate different 
pathways related to apoptosis.41,42 In the present study, it 
was found that DNC-induced cell death in U87MG and was 
compatible with activation of the apoptotic pathway in a 
time- and dose-dependent manner. Accordingly, caspase-3 
activation was increased by DNC. Previous studies reported 
that the induction of caspase-3 by curcumin in glioma cells 
may involve histone hypoacetylation43 and activation of the 
tumor necrosis factor-related apoptosis-inducing ligand 
(TRAIL/Apo2L) pathway.44 Formerly, the role of DNC in 
apoptosis induction was reported in A431 cells – a cell 
line model of epidermoid carcinoma – in a PARP (poly 
[adenosine diphosphate ribose] polymerase-dependent) 
pathway, indicating that DNC induces cancer cell death 
via triggering of the apoptosis pathways.23 The present 
study also demonstrates that DNC reduces the expression 
of stemness genes including OCT4 variants, SOX-2, and 
Nanog, an action that may limit carcinogenesis. Although 
Guo et al previously reported that there is a positive cor-
relation between the expression level of OCT4A, SOX-2, 
and Nanog in glioma and tumor malignancy in a grade-
dependent fashion,45 this is the first report showing that 
curcumin has an inhibitory role on OCT4, SOX-2, and 
Nanog pluripotency genes.
The function of miRNAs as regulators of genes involved 
in cell growth and proliferation is well established. Among 
these, miR-145 is one of the best characterized miRNAs in 
regulation of OCT4, SOX-2, and KLF-4 pluripotency genes. 
For the first time, Xu et al proved that miR-145 directly targets 
OCT4 and SOX-2 3′UTR.9 Downregulation of miR-145 in a 
wide range of tumors suggested that this miRNA acts as a 
tumor suppressor.11
In the present study, miR-145 levels were markedly 
elevated after treatment with DNC, compatible with the 
hypothesis that repression of OCT4 and SOX-2 is due 
to the upregulation of miR-145. Lee et al previously 
showed that overexpression of miR-145 can significantly 
inhibit migration and invasion of U87MG/U373MG 
cells.46 Although negative regulation of miR-145 on OCT4 
and SOX-2 has been demonstrated in glioma CD133 (+) 
cells,47 the present study shows for the first time that 
inhibition of OCT4 and SOX-2 by curcumin may occur 
through miR-145 overexpression. Therefore, miRNA can 
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be novel targets for natural chemopreventive agents as 
previously described.48
Conclusion
The novelty of this study is based on the effects of DNC on the 
pluripotency pathways of glioblastoma cells both at the level 
of gene expression and regulation. The data show that DNC 
efficiently suppresses glioblastoma cell growth by downregula-
tion of pluripotency genes, possibly in an miRNA-dependent 
manner. These results indicate that miRNAs may be used as 
possible targets for cancer therapy. On the other hand, the lack of 
DNC cytotoxicity in mesenchymal and fibroblast cells indicates 
that this new nanodrug can be considered a safe formulation to 
induce cancer cell death using a natural compound.
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Figure S1 The Fourier transform infrared spectrum of Oa400 shows a stretching band of c-h aliphatic at 2,921 cm-1, a stretching band of c-h unsaturated aliphatic at 
3,002 cm-1, and a stretching band carbonyl group of ester bands at 1,732 cm-1. The c-h bending vibration of ch2 and the c-h bending vibration of ch3 can be seen at 
1,462 cm-1 and 1,350 cm-1, respectively. The c-O stretching vibration was at 1,111 cm-1 as a broad band. The c=c stretching vibration can be seen at 1,651 cm-1.
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